Stock Analiz

Genmab A (GMAB) stock forecast and price target

Price $51.37 · data as of November 13, 2026

12-month price target

Average target$65.01
Upside / downside+26.6%
Analysts11
ConsensusStrong buy
Low $48.00Average $65.01High $80.00

Gold marker: average target · white marker: today’s price ($51.37)

Analyst ratings

Strong buy 1Buy 9Hold 2Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$1.26—$30.0B
Next fiscal year
ends December 31, 2027
$1.73—$36.3B
Next quarter
ends December 31, 2026
$0.20—$8.4B
Quarter after
ends March 31, 2027
$0.30—$7.2B

Consensus of the analysts covering Genmab A, updated daily. In the last 30 days 3 estimates were raised and 1 lowered.

Our model vs. Wall Street

Analysts see 26.6% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Genmab A’s intrinsic value about 35% above today’s market value, and it scores 2.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Genmab A stock price target?

The average 12-month target from 11 analysts is $65.01, 26.6% above the current price of $51.37 Targets range from $48.00 to $80.00.

Is Genmab A a buy according to analysts?

The consensus rating is “Strong buy” (1 strong buy, 9 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Genmab A expected to earn?

Analysts expect EPS of $1.26 for the fiscal year ending December 31, 2026 and $1.73 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.